Medical Cannabis: New study shows a reduction of medication intake for ADHD patient

Medical Cannabis: New study shows a reduction of medication intake for ADHD patient

Since the United States is struggling with cannabis research because it is still considered a Schedule 1 drug, other countries had to step up. Israel has been the most innovative so far and has been providing very interesting researches. Some even refer to Israel has "The Holy Land of medical marijuana."

Last month (January 2020) another refreshing research was published by the Rambam Maimonides Medical Journal. This new investigation was testing the impact of Cannabis on patients with ADHD. The results suggest that ADHD patients are prone to reduce their intake of prescription drugs such as psychostimulants like methylphenidate and amphetamine derivatives when they use medical cannabis.

Attention deficit hyperactivity disorder (ADHD) is a frequent and heritable disorder affecting 2.5%-5% of adults. This neurodevelopmental syndrome usually appears in childhood or early adolescence. It doesn't always become a lifetime condition but in 60%-70% of the cases, it persists into adulthood. People diagnosed with ADHD will have symptoms of inattention, hyperactivity, or impulsivity. Sadly, this can also lead to lower educational attainment and lower levels of employment.

Other studies had been led before, about the correlation between medical marijuana and the ADHD condition. Although these studies fixated on Delta-9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD) compounds. Those researches didn't demonstrate a significant reduction of ADHD symptoms.

This new study was more focused on exploring the role of the phytocannabinoids and the terpenes compounds found in cannabis than the action of THC and CBD precisely, regarding the ADHD condition.

For this research, the 59 participants had received an ADHD diagnosis from a physician and possessed a medical cannabis license. The patients were then asked to answer a detailed questionnaire about their conditions and medical cannabis experiences.

The results suggest that the consumption of medical cannabis containing high quantities of phytocannabinoids and terpenes are permitting ADHD patient to reduce their medications intake.

One lesser-known compound called Cannabinol (CBN) is also showing a lower score on the Adult ADHD Self-Report Scale (a psychological self-assessment to measure symptoms of ADHD)

In conclusion, ADHD is a frequent psychiatric disorder found in children adolescents and adults. It is unfortunately unrecognized, under-diagnosed, under-treated and often ends up coexisting with other psychiatric disorders. This new research can give ADHD patients hope of taking back control of their life. The results are showing a reduction of medication intake in people using medical cannabis containing high levels of phytocannabinoids (specifically CBN) and terpenes implying that a possible combined effect of the whole plant (entourage effect) might be the best way to use medical cannabis.

 

**These statements have not been evaluated by the Food & Drug Administration and are in no way intended to treat or diagnose any physical ailment or disease. Please consult your Doctor before adding CBD or any supplement to your diet. Most workplace and competitive sports drug screens focus on delta-tetrahydrocannabinol (THC) and do not screen for Cannabinol (CBD) or other legal and natural hemp-based compounds. Be advised, studies have shown that consuming hemp foods or oils can cause a positive result when screening urine and blood specimens. Therefore, if you are subject to any form of drug testing or screening. We recommended (as does the United States Armed Services) that you DO-NOT ingest CBD or hemp oil before consulting your healthcare practitioner or your drug screening testing company or employer.